KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Other Non-Current Assets (2016 - 2025)

Rigel Pharmaceuticals has reported Other Non-Current Assets over the past 16 years, most recently at $1.9 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $1.9 million for Q4 2025, up 24.95% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (up 24.95% YoY), and the annual figure for FY2025 was $1.9 million, up 24.95%.
  • Other Non-Current Assets for Q4 2025 was $1.9 million at Rigel Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for RIGL hit a ceiling of $5.0 million in Q3 2023 and a floor of $403000.0 in Q2 2022.
  • Median Other Non-Current Assets over the past 5 years was $1.1 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Other Non-Current Assets: soared 923.97% in 2023 and later plummeted 75.49% in 2025.
  • Rigel Pharmaceuticals' Other Non-Current Assets stood at $974000.0 in 2021, then tumbled by 34.29% to $640000.0 in 2022, then soared by 377.34% to $3.1 million in 2023, then crashed by 50.02% to $1.5 million in 2024, then grew by 24.95% to $1.9 million in 2025.
  • The last three reported values for Other Non-Current Assets were $1.9 million (Q4 2025), $1.2 million (Q3 2025), and $4.2 million (Q2 2025) per Business Quant data.